New drug candidate targets cancer therapy resistance effectively

Researchers at the University of Michigan have developed a new drug candidate, MTX-531, which targets two key drivers of cancer therapy resistance: EGFR and PI3K. In preclinical studies, MTX-531 showed tumor regression in mouse models of head and neck cancer and was effective against KRAS-mutated gastrointestinal tumors. Unlike other PI3K inhibitors, it does not cause hyperglycemia, suggesting a potentially less toxic treatment option.